Fluctuation of Anti-Domain 1 and Anti-β
Journal
Arthritis & rheumatology (Hoboken, N.J.)
ISSN: 2326-5205
Titre abrégé: Arthritis Rheumatol
Pays: United States
ID NLM: 101623795
Informations de publication
Date de publication:
06 2023
06 2023
Historique:
revised:
07
12
2022
received:
12
09
2022
accepted:
24
01
2023
medline:
1
6
2023
pubmed:
28
1
2023
entrez:
27
1
2023
Statut:
ppublish
Résumé
The present study was undertaken to longitudinally evaluate titers of antibodies against β Patients with available blood samples from at least 4 time points (at baseline [year 1] and at years 2-4 of follow-up) were included. Detection of anti-β Among 230 patients in the study cohort, anti-D1 and anti-β Treatment with HCQ and incident vascular events in aPL-positive patients predicted significant anti-D1 and anti-β
Substances chimiques
Antibodies, Antiphospholipid
0
Autoantibodies
0
beta 2-Glycoprotein I
0
Banques de données
ClinicalTrials.gov
['UL1TR000457']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
984-995Investigateurs
Guillermo Pons-Estel
(G)
Bill Giannakopoulos
(B)
Steve Krilis
(S)
Guilherme de Jesus
(G)
Roger Levy
(R)
Flavio Signorelli
(F)
Danieli Andrade
(D)
Gustavo Balbi
(G)
Ann E Clarke
(AE)
Leslie Skeith
(L)
Paul R Fortin
(PR)
Lanlan Ji
(L)
Zhouli Zhang
(Z)
Chengde Yang
(C)
Hui Shi
(H)
Stephane Zuily
(S)
Denis Wahl
(D)
Maria G Tektonidou
(MG)
Cecilia Nalli
(C)
Laura Andreoli
(L)
Angela Tincani
(A)
Cecilia B Chighizola
(CB)
Maria Gerosa
(M)
Pier Luigi Meroni
(PL)
Vittorio Pengo
(V)
Chunyan Cheng
(C)
Giulia Pazzola
(G)
Savino Sciascia
(S)
Silvia Foddai
(S)
Massimo Radin
(M)
Stacy Davis
(S)
Olga Amengual
(O)
Tatsuya Atsumi
(T)
Imad Uthman
(I)
Maarten Limper
(M)
Philip de Groot
(P)
Guillermo Ruiz-Irastorza
(G)
Amaia Ugarte
(A)
Ignasi Rodriguez-Pinto
(I)
Ricard Cervera
(R)
Giuseppe Barilaro
(G)
Roberto Ríos-Garcés
(R)
Jose Pardos-Gea
(J)
Esther Rodriguez Almaraz
(ER)
Maria Jose Cuadrado
(MJ)
Maria Angeles Aguirre Zamorano
(MAA)
Chary Lopez-Pedrera
(C)
Bahar Artim-Esen
(B)
Murat Inanc
(M)
Maria Laura Bertolaccini
(ML)
Hannah Cohen
(H)
Maria Efthymiou
(M)
Munther Khamashta
(M)
Ian Mackie
(I)
Giovanni Sanna
(G)
Jason Knight
(J)
Yu Zuo
(Y)
Michelle Petri
(M)
Rebecca K Leaf
(RK)
Robert Roubey
(R)
Thomas Ortel
(T)
Emilio Gonzalez
(E)
Rohan Willis
(R)
Nina Kello
(N)
Michael Belmont
(M)
Steven Levine
(S)
Jacob Rand
(J)
Medha Barbhaiya
(M)
Doruk Erkan
(D)
Jane Salmon
(J)
Michael Lockshin
(M)
Ali A Duarte Garcia
(AA)
D Ware Branch
(DW)
Informations de copyright
© 2023 The Authors. Arthritis & Rheumatology published by Wiley Periodicals LLC on behalf of American College of Rheumatology.
Références
Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295-306.
Chighizola CB, Gerosa M, Meroni PL. New tests to detect antiphospholipid antibodies: anti-domain I β-2-glycoprotein-I antibodies. Curr Rheumatol Rep 2014;16:402.
Clinical and Laboratory Standards Institute. Defining, establishing, and verifying reference intervals in the clinical laboratory, 3rd edition. CLSI document EP28-A3c. Wayne (PA): Clinical and Laboratory Standards Institute; 2015.
Devreese KM, Ortel TL, Pengo V, et al. Subcommittee on lupus anticoagulant/antiphospholipid A: laboratory criteria for anti-phospholipid syndrome: communication from the SSC of the ISTH. J Thromb Haemost 2018;16:809-13.
Gkrouzman E, Sevim E, Finik J, et al. Antiphospholipid antibody profile stability over time: prospective results from the APS ACTION clinical database and repository. J Rheumatol 2021;48:541-7.
Liang EY, Ke PF, Li GH, et al. Performance evaluation of antiphospholipid antibodies on INOVA quanta flash system. Clin Lab. 2021;67.
Sciascia S, Coloma-Bazán E, Radin M, et al. Can we withdraw anticoagulation in patients with antiphospholipid syndrome after seroconvertion? Autoimmun Rev 2017;16:1109-14.
Girón-González JA, García del Río E, Rodríguez C, et al. Antiphospholipid syndrome and asymptomatic carriers of antiphospholipid antibody: prospective analysis of 404 individuals. J Rheumatol 2004;31:1560-7.
Riancho-Zarrabeitia L, Daroca G, Muñoz P, et al. Serological evolution in women with positive antiphospholipid antibodies. Semin Arthritis Rheum 2017;47:397-402.
Yelnik CM, Urbanski G, Drumez E, et al. Anticoagulation withdrawal in antiphospholipid syndrome: a retrospective matched-control study. Lupus 2018;27:357-64.
Erkan D, Derksen WJ, Kaplan V, et al. Real world experience with antiphospholipid antibody tests: how stable are results over time? Ann Rheum Dis 2005;64:1321-5.
Radin M, Schreiber K, Sciascia S, et al. Prevalence of antiphospholipid antibodies negativisation in patients with antiphospholipid syndrome: a long-term follow-up multicentre study. Thromb Haemost 2019;119:1920-6.
Amory CF, Levine SR, Brey RL, et al. Antiphospholipid antibodies and recurrent thrombotic events: persistence and portfolio. Cerebrovasc Dis 2015;40:293-300.
Martinez-Berriotxoa A, Ruiz-Irastorza G, Egurbide MV, et al. Transiently positive anticardiolipin antibodies and risk of thrombosis in patients with systemic lupus erythematosus. Lupus 2007;16:810-6.
Zen M, Martinez ML, Benvenuti F, et al. Prevalence, outcome and management of patients with SLE and secondary antiphospholipid antibody syndrome after aPL seroconversion. Rheumatology (Oxford) 2021;60:1313-20.
Out HJ, de Groot PG, Hasselaar P, et al. Fluctuations of anticardiolipin antibody levels in patients with systemic lupus erythematosus: a prospective study. Ann Rheum Dis 1989;48:1023-8.
Out HJ, van Vliet M, de Groot PG, et al. Prospective study of fluctuations of lupus anticoagulant activity and anticardiolipin antibody titre in patients with systemic lupus erythematosus. Ann Rheum Dis 1992;51:353-7.
Chighizola CB, Andreoli L, Gerosa M, et al. The treatment of anti-phospholipid syndrome: a comprehensive clinical approach. J Autoimmun 2018;90:1-27.
Kravvariti E, Koutsogianni A, Samoli E, et al. The effect of hydroxychloroquine on thrombosis prevention and antiphospholipid antibody levels in primary antiphospholipid syndrome: a pilot open label randomized prospective study. Autoimmun Rev 2020;19:102491.
Nuri E, Taraborelli M, Andreoli L, et al. Long-term use of hydroxychloroquine reduces antiphospholipid antibodies levels in patients with primary antiphospholipid syndrome. Immunol Res 2017;65:17-24.
Emmi G, Bettiol A, Palterer B, et al. Belimumab reduces antiphospholipid antibodies in SLE patients independently of hydroxychloroquine treatment. Autoimmun Rev 2019;18:312-4.
Petri M. Use of hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in antiphospholipid antibody-positive patients. Curr Rheumatol Rep 2011;13:77-80.
Kaiser R, Cleveland CM, Criswell LA. Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multi-ethnic cohort. Ann Rheum Dis 2009;68:238-41.
Bessant R, Duncan R, Ambler G, et al. Prevalence of conventional and lupus-specific risk factors for cardiovascular disease in patients with systemic lupus erythematosus: a case-control study. Arthritis Rheum 2006;55:892-9.
Mok MY, Chan EY, Fong DY, et al. Antiphospholipid antibody profiles and their clinical associations in Chinese patients with systemic lupus erythematosus. J Rheumatol 2005;32:622-8.
Roman MJ, Shanker BA, Davis A, et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003;349:2399-406.
Petri M. Thrombosis and systemic lupus erythematosus: the Hopkins Lupus Cohort perspective. Scand J Rheumatol 1996;25:191-3.
Mok CC, Tang SS, To CH, et al. Incidence and risk factors of thromboembolism in systemic lupus erythematosus: a comparison of three ethnic groups. Arthritis Rheum 2005;52:2774-82.
Ho KT, Ahn CW, Alarcón GS, et al. Systemic lupus erythematosus in a multiethnic cohort (LUMINA): XXVIII. Factors predictive of thrombotic events. Rheumatology (Oxford) 2005;44:1303-7.
Hsu CY, Lin YS, Su YJ, et al. Effect of long-term hydroxychloroquine on vascular events in patients with systemic lupus erythematosus: a database prospective cohort study. Rheumatology (Oxford) 2017;56:2212-21.
Gómez-Pacheco L, Villa AR, Drenkard C, et al. Serum anti-β2-glycoprotein-I and anticardiolipin antibodies during thrombosis in systemic lupus erythematosus patients. Am J Med 1999;106:417-23.
Veneri D, Ambrosetti A, Franchini M, et al. Remission of severe antiphospholipid syndrome associated with non-Hodgkin's B-cell lymphoma after combined treatment with rituximab and chemotherapy. Haematologica 2005;90 Suppl:ECR37.
Bakshi J, Stevens R. Rituximab therapy for recurrent thromboembolic disease in antiphospholipid syndrome. Lupus 2013;22:865-7.
Gkogkolou P, Ehrchen J, Goerge T. Severe antiphospholipid antibody syndrome-response to plasmapheresis and rituximab. J Dermatolog Treat 2017;28:564-6.
Gamoudi D, Cutajar M, Gamoudi N, et al. Achieving a satisfactory clinical and biochemical response in antiphospholipid syndrome and severe thrombocytopenia with rituximab: two case reports. Clin Case Rep 2017;5:845-8.
Pons I, Espinosa G, Cervera R. Efficacy and safety of rituximab in the treatment of primary antiphospholipid syndrome: analysis of 24 cases from the bibliography review. Med Clin (Barc) 2015;144:97-104.
You Y, Shi C, Zhou Z, et al. Rituximab in thrombotic primary antiphospholipid syndrome: a pilot study from a single centre in China. Ann Rheum Dis 2021;80:820-2.
Agmon-Levin N, Berman M, Harel L, et al. Rituximab for refractory manifestations of the antiphospholipid syndrome: a multicentre Israeli experience. Clin Exp Rheumatol 2021;39:1049-55.
Yazici A, Yazirli B, Erkan D. Belimumab in primary antiphospholipid syndrome. Lupus 2017;26:1123-4.
Klemm P, Müller-Ladner U, Tarner IH, et al. Belimumab reduces antiphospholipid antibodies in primary triple-positive antiphospholipid syndrome. Autoimmun Rev 2020;19:102594.
Stohl W, Hiepe F, Latinis KM, et al. Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus. Arthritis Rheum 2012;64:2328-37.
Chatzidionysiou K, Samoli E, Sfikakis PP, et al. Response to: ‘Association of subcutaneous belimumab and long-term antimalarial treatment reduces antiphospholipid antibodies levels in systemic lupus erythematosus: post-hoc analysis of a randomised placebo-controlled trial-comment on: ‘Effect of belimumab treatment on antiphospholipid antibody levels: post-hoc analysis based on two randomised placebo-controlled trials in systemic lupus erythematosus’ by Chatzidionysiou et al’ by Bettiol et al. Ann Rheum Dis 2022;81:e141.
Bettiol A, Pregnolato F, Sciascia S, et al. Association of subcutaneous belimumab and long-term antimalarial treatment reduces antiphospholipid antibodies levels in systemic lupus erythematosus: post-hoc analysis of a randomised placebo-controlled trial-comment on: ‘Effect of belimumab treatment on antiphospholipid antibody levels: post-hoc analysis based on two randomised placebo-controlled trials in systemic lupus erythematosus’ by Chatzidionysiou et al. Ann Rheum Dis. 2022;81:e140.
Sciascia S, Rubini E, Radin M, et al. Anticardiolipin and anti-β2 glycoprotein-I antibodies disappearance in patients with systemic lupus erythematosus and antiphospholipid syndrome while on belimumab. Ann Rheum Dis 2018;77:1694-5.
Cavazzana I, Kumar R, Pozzari C, et al. Autoantibodies’ titre modulation by anti-BlyS treatment in systemic lupus erythematosus. Lupus 2019;28:1074-81.
Ginzler EM, Wallace DJ, Merrill JT, et al. Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus. J Rheumatol 2014;41:300-9.
Drenkard C, Sánchez-Guerrero J, Alarcón-Segovia D. Fall in antiphospholipid antibody at time of thromboocclusive episodes in systemic lupus erythematosus. J Rheumatol 1989;16:614-7.
Alarcón-Segovia D, Delezé M, Oria CV, et al. Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus. A prospective analysis of 500 consecutive patients. Medicine (Baltimore) 1989;68:353-65.
Khawaja M, Magder L, Goldman D, et al. Loss of antiphospholipid antibody positivity post-thrombosis in SLE. Lupus Sci Med 2020;7:e000423.
McDonnell T, Wincup C, Buchholz I, et al. The role of β-2-glycoprotein I in health and disease associating structure with function: more than just APS. Blood Rev 2020;39:100610.
Linden A. Assessing regression to the mean effects in health care initiatives. BMC Med Res Methodol 2013;13:119.